Catabasis Pharmaceuticals Will Present CAT-1004, a Potential Disease-Modifying Agent in Development for the Treatment of Duchenne Muscular Dystrophy, at the World Muscle Society Congress

Catabasis Pharmaceuticals, Inc. CATB, a clinical-stage drug development company built on a pathway pharmacology technology platform, today announced that Catabasis will present CAT-1004 for the treatment of Duchenne muscular dystrophy (DMD) and the MoveDMD trial design at the World Muscle Society Congress. The World Muscle Society Congress will be held September 30 – October 4, 2015, in Brighton, United Kingdom, at the Brighton Dome. Joanne Donovan, M.D., Ph.D., chief medical officer of Catabasis, will present a poster titled "CAT-1004, an oral agent targeting NF-kB in development for treatment of Duchenne muscular dystrophy: Phase 1 / 2 study design." The poster presentation will take place in the Drug Therapies for DMD session on Friday, October 2, 2015, from 3:00pm – 4:30pm local time in the Brighton Dome.